Effective mood stabilization with a chelated mineral micronutrient treatment: an open-label trial in bipolar disorder.

A group of scientists at the University of Calgary and the Alberta Children’s Hospital conducted a study to determine the therapeutic benefit of EMPowerplus on 14 unselected adult bipolar patients who had taken psychotropic medications for an average of 6.7 years. Patients were assessed by their own psychiatrists with the Hamilton Rating Scale for Depression (HAM-D), the Brief Psychiatric Rating Scale (BPRS), and the Young Mania Rating Scale (YMRS).

Results: For the 11 patients who completed the minimum 6-month open trial, average symptom reduction was 55% on the HAM-D, 60% on the BPRS, and 66% on the YMRS. The effect size for the intervention was large (>.8) for each measure. The number of psychotropic medications decreased significantly from an average of 2.7 to 1.0. In some cases, the micronutrient treatment replaced psychotropic medications and the patients remained stable. The only reported side effect (i.e., nausea) was infrequent, minor, and transitory.

read study

last study

study index

next study